🔎 Trials Near Me

Gara Jalqabaatti › Kansa Endometiriyaalii › Tennessee › Nashville

Qorannoo klinikaalii Kansa Endometiriyaalii Nashville, TN keessatti

Qorannoo 38 Kansa Endometiriyaalii f Nashville fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.

Takkalaa qorannoo (Ingiliffa)

Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Namoota walitti qabaa jiraSadarkaa 3
  • Vanderbilt Breast Center at One Hundred Oaks, Nashville
  • Vanderbilt University/Ingram Cancer Center, Nashville
  • Vanderbilt-Ingram Cancer Center Cool Springs, Franklin · Miili 17 fagaatti
Umuriin 18 fi ol · Dubartoota · Haaromfame 05-Onk-2026 · NCT07198074

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Namoota walitti qabaa jiraSadarkaa 2
  • Vanderbilt Breast Center at One Hundred Oaks, Nashville
  • Vanderbilt University/Ingram Cancer Center, Nashville
Umuriin hundi · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT05564377

A Study of PHST001 in Advanced Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
  • Vanderbilt-Ingram Cancer Center, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06840886

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • Tennessee Oncology, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06270706

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Namoota walitti qabaa jiraSadarkaa 1/2
  • Sarah Cannon Research Institute, Nashville
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT04585750

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Namoota walitti qabaa jiraSadarkaa 1
  • SCRI Oncology Partners, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT07419841

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Namoota walitti qabaa jiraSadarkaa 2
  • SCRI Oncology Partners, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06172478

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • Sarah Cannon Research Institute (SCRI), Nashville
Umuriin 19 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06586957

DESTINY-PANTUMOUR04

Namoota walitti qabaa jiraQorannoo ilaalaa
  • Research Site, Nashville
Umuriin 18 hanga 130 · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT07124000

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • Research Site, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06218914

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Namoota walitti qabaa jiraSadarkaa 2
  • Research Site, Nashville
Umuriin 18 hanga 130 · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT05489211

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1/2
  • Sarah Cannon Research Institue, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT06128551

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • Sarah Cannon - Tennessee Oncology, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 21-Ful-2026 · NCT05983432

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Namoota walitti qabaa jiraSadarkaa 1/2
  • Sarah Cannon Nashville, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT07109726

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1/2
  • GSK Investigational Site, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT07213609

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • Sarah Cannon Research Institute, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Ful-2026 · NCT06293898

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

Namoota walitti qabaa jiraSadarkaa 1
  • Sarah Cannon Research Institute, Nashville
Umuriin 18 fi ol · Dubartoota · Haaromfame 03-Ful-2026 · NCT07755436

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • Vanderbilt-Ingram Cancer Center, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT06515613

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • SCRI Oncology Partners - Nashville, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 26-Hag-2026 · NCT07383506

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • SCRI Oncology Partners, Nashville
Umuriin 15 fi ol · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT06276491

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • Normunity Investigational Site, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Hag-2026 · NCT07182149

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1/2
  • Sarah Cannon Research Institute, Nashville
  • Vanderbilt Ingram Cancer Center, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Hag-2026 · NCT05919264

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1/2
  • Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Hag-2026 · NCT05592626

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

Namoota walitti qabaa jiraSadarkaa 1/2
  • SCRI Oncology Partners, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Hag-2026 · NCT06330064

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Namoota walitti qabaa jiraSadarkaa 1/2
  • Sarah Cannon Research Institute at Tennessee Oncology, Nashville
  • Tennessee Oncology, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Hag-2026 · NCT05579366

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1/2
  • SCRI Oncology Partners, Nashville
  • Vanderbilt Medical Center, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ado-2026 · NCT04657068

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Namoota walitti qabaa jiraSadarkaa 3
  • Research Site, Nashville
Umuriin 18 fi ol · Dubartoota · Haaromfame 29-Ado-2026 · NCT07044336

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Namoota walitti qabaa jiraSadarkaa 2
  • SCRI Oncology Partners, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Ado-2026 · NCT06695845

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1/2
  • Sarah Cannon Research Institute, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 07-Ado-2026 · NCT05768139

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1/2
  • Sarah Cannon Research Institute (SCRI), Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Wax-2026 · NCT05377996

A Study of LY4175408 in Participants With Advanced Cancer

Namoota walitti qabaa jiraSadarkaa 1
  • Sarah Cannon Research Institute, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Wax-2026 · NCT07046923

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

Namoota walitti qabaa jiraSadarkaa 1
  • SCRI Oncology Partners, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Wax-2026 · NCT07503808

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1/2
  • Sarah Cannon Research Institute, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 06-Cam-2026 · NCT06239194

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
  • Vanderbilt-Ingram Cancer Center, Nashville
Umuriin 40 fi ol · Saalaa hunda · Haaromfame 20-Ama-2026 · NCT05366881

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Namoota walitti qabaa jiraQorannoo ilaalaa
  • Massive Bio SYNERGY-AI site, Nashville
Umuriin hundi · Saalaa hunda · Haaromfame 28-Onk-2025 · NCT03452774

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1/2
  • Tennessee Oncology, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ful-2025 · NCT05941507

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

Namoota walitti qabaa jiraSadarkaa 1/2
  • Verdi Oncology Tennessee, Scri Oncology Partners, Nashville
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Gur-2025 · NCT05669430

Qorannoo Kansa Endometiriyaalii magaalota biroo keessatti

Qorannoo biroo Nashville keessatti

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.